real-world data
FDA Announces New Rare Disease Approval Programme
FDA; rare disease; conditional approval pathway; accelerated approval; biologics; drug review; surrogate endpoints; real-world data; streamlined process
Boehringer Ingelheim Expands Oncology Pipeline via Strategic Collaboration with Tempus AI
Boehringer Ingelheim; Tempus AI; oncology; cancer research; real-world data; AI; biomarker discovery; drug development; strategic collaboration